CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration. Am J Clin Pathol 2017 Nov 20;148(6):485-493
Date
11/11/2017Pubmed ID
29126177DOI
10.1093/ajcp/aqx097Scopus ID
2-s2.0-85038129680 (requires institutional sign-in at Scopus site) 11 CitationsAbstract
OBJECTIVES: CD30 is a protein thought to promote cell proliferation/survival and downregulate the immune response. Twenty percent to 40% of de novo diffuse large B-cell lymphomas (DLBCLs) express CD30, and some patients have been treated with the anti-CD30 agent brentuximab. In the solid organ transplant setting, allograft regulatory T cells (Tregs) have been shown to be modulated via CD30 signaling.
METHODS: Posttransplant lymphoproliferative disorders (PTLDs) constitute a heterogeneous group of lymphomas, and since CD30 expression has been rarely formally assessed in PTLDs, we analyzed a cohort of PTLDs.
RESULTS: We found that 26 (79%) of 33 PTLDs were CD30+. Of these, 17 (77%) of 22 DLBCL monomorphic PTLDs were CD30+ compared with 56 (38%) of 148 de novo DLBCLs (P = .009). The median FoxP3+ Treg count was higher in CD30+ than in CD30- PTLDs, 3.0 vs 0 (P = .012).
CONCLUSIONS: These findings suggest a pathophysiologic link between CD30 activity and Tregs and may indicate differential expression of CD30 in B-cell lymphomas arising in the setting of immune dysregulation.
Author List
Hartley C, Vaughan JW, Jarzembowski J, Kroft SH, Hosking P, Harrington AM, Olteanu HAuthors
Alexandra M. Harrington MD Professor in the Pathology department at Medical College of WisconsinJason A. Jarzembowski MD, PhD Sr Associate Dean, CEO CSG, Professor in the Pathology department at Medical College of Wisconsin
Steven Howard Kroft MD Chair, Professor in the Pathology department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdultAged
Epstein-Barr Virus Infections
Female
Humans
Ki-1 Antigen
Lymphoma, Large B-Cell, Diffuse
Lymphoproliferative Disorders
Male
Middle Aged
Neoplasms, Second Primary
T-Lymphocytes, Regulatory
Young Adult